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ABSTRACT 1 
Colorectal cancer (CRC) is amongst the most commonly diagnosed cancers and causes of death from 2 
cancer across the world. CRC can, however, be detected in asymptomatic patients at a curable stage, 3 
and several studies have shown lower mortality among patients who undergo screening compared to 4 
those who do not. Using colonoscopy in CRC screening also results in the detection of precancerous 5 
polyps that can be directly removed during the procedure, thereby reducing the incidence of cancer. 6 
In the past decade, convincing evidence has appeared that the effectiveness of colonoscopy as CRC 7 
prevention tool is associated with the quality of the procedure. This review aims to provide an up-to-8 
date overview of recent efforts to improve colonoscopy effectiveness of by enhancing detection and 9 
improving the completeness and safety of resection of colorectal lesions.  10 
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INTRODUCTION  1 
Approximately 50 years after the introduction of diagnostic colonoscopy and polypectomy
1, 2
, 2 
colonoscopy is firmly entrenched across much of the world as one of the most commonly performed 3 
and valuable procedures in clinical medicine. In many countries, colonoscopy is the primary imaging 4 
test to evaluate patients with colorectal symptoms, particularly those with bleeding. Colorectal 5 
bleeding in its various forms, including hematochezia, iron deficiency anemia, melena with a negative 6 
upper endoscopy, and positive fecal blood test, has a substantially higher predictive value for 7 
colorectal cancer (CRC) compared to colonoscopy in patients with non-bleeding symptoms or no 8 
symptoms 
3, 4
. Excellent detection as well as same session biopsy and potentially also treatment have 9 
made colonoscopy the test of choice in bleeding patients.   10 
In addition to prevention of colorectal cancer deaths through detection of curable cancers, 11 
colonoscopy can also prevent most incident cancers. As CRC develops gradually from premalignant 12 
adenomatous and serrated polyps, colonoscopy with polypectomy provides an opportunity to halt 13 
this process. Evidence for cancer prevention by colonoscopy is found in a randomized controlled trial 14 
of fecal blood testing 
5
, a surveillance study 
6
, cohort 
7
 and case control studies 
8-10
, and in large trials 15 
evaluating variable detection 
11, 12
. CRC prevention via colonoscopy is achieved through effective 16 
detection and resection of precancerous lesions. No other available imaging technique matches or 17 
even approaches the sensitivity of colonoscopy for precancerous lesions, particularly for serrated 18 
polyps 
13
. 19 
Despite its strengths, colonoscopy has certain disadvantages and limitations. Colonoscopy 20 
has a relatively long learning curve, and fully trained colonoscopists demonstrate marked variation in 21 
polyp detection 
14, 15
, cancer prevention 
11, 12
, polyp resection 
16
, and use of appropriate screening and 22 
surveillance intervals 
17
. Colonoscopy carries risks associated with bowel preparation, sedation, 23 
aspiration, perforation, and splenic injury. Patients subjected to resection of all exposed lesions 24 
sometimes suffer post-polypectomy hemorrhage, including from lesions with an extremely low risk 25 
of ever causing harm, and which would not have been detected by other imaging or screening 26 
modalities.   27 
Delivering high quality colonoscopies should be the aim of all endoscopists. In this review we 28 
summarize ongoing efforts to improve the quality of colonoscopy as a detection and resection tool, 29 
as well as efforts to improve its safety and cost-effectiveness.  30 
 31 
QUALITY IN COLONOSCOPY 32 
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 Colonoscopy is currently regarded as the reference standard to detect and prevent CRC. It is 1 
widely practiced and generally safe and accurate, but not perfect. In the past decade, worldwide 2 
awareness on the importance of quality assurance of colonoscopy has emerged. Tandem 3 
colonoscopy studies, in which patients undergo colonoscopy twice in the same day, provided the first 4 
direct evidence that colonoscopy systematically misses small colorectal polyps, and some larger 5 
polyps 
18, 19
. Further, there was evidence that some endoscopists missed more polyps than others, 6 
and this variable detection was shortly associated with examination technique during withdrawal 
20
. 7 
An audit study in 2003 in the UK identified a remarkably low adjusted cecal intubation rate of only 8 
56.9%, demonstrating that in some countries poor performance extended to insertion technique and 9 
the ability to achieve complete examinations 
21
. These findings were the origins of widespread efforts 10 
to improve colonoscopy performance and reduce operator dependence in basic colonoscopy 11 
outcomes. Subsequently, a vast amount of research on quality and accuracy of this procedure has 12 
appeared in literature.  13 
Regarding detection, colonoscopy is not fully protective for the development of post-14 
colonoscopy CRCs, which are disproportionately located in the right-sided colon 
8, 22-26
. Post-15 
colonoscopy (interval) CRCs are defined as CRCs diagnosed after a complete negative or clearing 16 
colonoscopy and diagnosed before the recommended surveillance or screening interval 
27
. The 17 
majority of those post-colonoscopy cancers appears to be the result of procedural related factors 18 
and not related to patient- or biological factors 
27
. This is supported by a study reporting that 23% of 19 
patients with a newly diagnosed CRC larger than 2 cm had undergone a colonoscopy within the 20 
preceding 30 months 
28
. Certainly to achieve optimal effectiveness of this invasive procedure, the 21 
procedure should have proper indications, the interval between surveillance intervals should be 22 
consistent with guideline recommendations, and the benefits of the procedure should outweigh the 23 
complication risk, burden and other disadvantages of an invasive procedure.  24 
In an effort to assess the quality of colonoscopy between endoscopists and practices, various 25 
quality indicators have been proposed in guidelines 
29-32
. Ideally such indicators are based upon clear 26 
evidence, and for several parameters such evidence is available. For each phase of the colonoscopy, 27 
i.e. preprocedure, intraprocedure and postprocedure, registration of quality indicators is 28 
recommended (TABLE A) 
29
.  29 
A colonoscopy is only complete and accurate if the whole colon, including the cecum, is 30 
visualized. Low cecal intubation rates (CIRs) have been associated with higher rates of proximal post-31 
colonoscopy cancers 
33
. Therefore, cecal intubation should be confirmed and photodocumented by 32 
endoscopic pictures of the cecal landmarks, ileocecal valve and appendiceal orifice. Effective 33 
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endoscopists should achieve cecal intubation rates of at least 90%, and when adjusted for strictures, 1 
stenosis and poor bowel preparation or in healthy adults with an indication of screening at least 95% 2 
29-32
. 3 
 To ensure safe intubation and optimal inspection, adequate bowel preparation is 4 
indispensable. Poor bowel cleansing has been associated with incomplete colonoscopy, prolonged 5 
procedure time and reduced yield. Studies demonstrating the correlation between bowel prep 6 
quality and post-colonoscopy CRCs are, however, not available yet
31
. Assessment of the quality of the 7 
bowel preparation is essential and should be documented with a validated scale, for example the 8 
Boston Bowel Preparation Score (BBPS)
34
. This score is used after optimal cleaning and rinsing, and 9 
thus a judgment of the final situation at which inspection took place. BBPS scores of ≥ 2 in each of 10 
three colon segments correlated with adequate bowel cleansing
35
, and should allow the 11 
colonoscopist to recommend a screening or surveillance interval appropriate to the findings of the 12 
examination, without the need to shorten the recommended interval based on preparation quality.  13 
Consistent with this conclusion, segmental scores of ≥ 2 predict a lower risk of polyps in that segment 14 
at follow up colonoscopy
36
. 15 
The bowel-cleansing regimen is regarded as burdensome by many patients. The optimal 16 
bowel preparation is effective, tolerable and safe, also for individuals with comorbidities. Multiple 17 
regimens exist, which can be roughly divided into high and low volume preparations. The high 18 
volume preparations are the 4 liter polyethylene glycol -electrolyte lavage solutions (PEG-ELS), which 19 
are suitable for all patients and which, when given in split doses, are likely the gold standard for 20 
effectiveness. 4 L PEG-ELS causes less fluid and electrolyte shifts than hyperosmotic preparations, 21 
and are often preferred for patients with renal insufficiency, heart failure, and decompensated liver 22 
disease.  Because of their high level of effectiveness, 4L PEG-ELS preparations are preferred in many 23 
units for patients with clinical features that predict difficulty achieving adequate preparation, 24 
including those with chronic constipation, obesity, diabetes mellitus, and those on opioids or 25 
tricyclics. Patients with a history of ineffective preparation are often given >4L of PEG-ELS.  26 
Conversely, high volume is often difficult to tolerate and some patients cannot complete ingestion.  27 
For many healthy outpatients, low volume preparations provide high quality preparation and 28 
improved tolerance. Hyperosmotic , low volume preparations based on sodium phosphate or sodium 29 
sulfate are effective, though rare instances of renal failure from sodium phosphate have markedly 30 
reduced its use in the U.S..  Other low volume preparations include combinations of 2L PEG-ELS plus 31 
ascorbate, and in the U.S there is substantial use of non-FDA approved regimens based on PEG3350 32 
in sport drinks, or on magnesium citrate, or combinations of these agents. Other low volume 33 
preparations include combinations of 2L PEG-ELS plus ascorbate as well as “home-made” 34 
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preparations based on PEG3350 in sport drinks, which is often combined with magnesium citrate. 1 
Split-dosing, i.e. giving half the regimen the evening before colonoscopy and half on the morning of 2 
colonoscopy, improves bowel prep quality and detection compared to evening before regimens.  3 
“Same-day” dosing, in which the entire preparation is given the morning of colonoscopy, is also 4 
effective. The US Multi-Society Task Force recommended that colonoscopy programs should be able 5 
to achieve adequate bowel preparation in at least 85% of outpatient examinations
37
. This document 6 
as well as the European guideline can be consulted for best practice
37, 38
. 7 
Thorough inspection of the colonic mucosa is crucial to optimize its effectiveness. Most 8 
mucosal inspection takes place during withdrawal of the endoscope from cecum to rectum. Taking at 9 
least 6 or more minutes to inspect the colonic mucosa is associated with an increase in adenoma 10 
detection rate (ADR).
14
 The ADR is currently considered one of the most important evidence-based 11 
quality indicators for colonoscopy. Two landmark papers have demonstrated that the ADR of 12 
individual endoscopists is associated with the risk of post-colonoscopy CRCs 
11, 12
. Patients scoped by 13 
a colonoscopist with an ADR of <20% had a 10 times higher risk for post-colonoscopy cancer than 14 
when scoped by an endoscopist with an ADR >20% 
11, 12
. Most guidelines recommend an ADR of at 15 
least 20-25% in screening colonoscopies. Although a clear evidence-based quality indicator, ADR also 16 
has some inherent limitations. First, the target ADR depends on the population scoped. When 17 
colonoscopy is used as a primary screening method, average ADR is expected to be relatively low but 18 
above 20-25% 
29-32
, whereas ADRs in FIT-positive screenees have a much higher median of at least 19 
around 50% 
39, 40
. Other risk factors like patients’ sex also heavily influence target ADRs 
41
. Besides, 20 
the ADR does not evaluate the total number of adenomas per individual patient, which is especially 21 
important in populations with high ADRs like FIT-positive screenees. To measure ADR, the 22 
histopathology result must often be manually derived from a pathology database, making it a more 23 
complicated parameter for monitoring purposes. However, while conventional adenomas are the 24 
clear precursors of the majority of colorectal cancers, some serrated lesions (sessile serrated lesions 25 
and traditional serrated adenomas) are precursors for CRC and should also be detected and 26 
removed. Those serrated polyps are not included in ADRs. A few recent studies suggested the 27 
proximal serrated polyp detection rate as quality parameter for high quality colonoscopy, however 28 
the association between a serrated polyp detection rate and post-colonoscopy CRCs has yet to be 29 
determined 
42, 43
.  Further, differentiation of hyperplastic polyps (which are generally considered to 30 
not be precancerous) from sessile serrated lesions is still generally subject to large interobserver 31 
variation in pathology interpretation 
44
, which complicates developing an endoscopic quality target 32 
for detection of sessile serrated lesions. 33 
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Resection is an emerging area for quality measurement. A single center study found that 1 
effective eradication of polyps 5-20 mm in size varied 3 fold between endoscopists
16
. A tool 2 
developed and validated in Europe to assess polypectomy competency (The Direct Observation of 3 
Polypectomy Skills or DOPyS) 
45
  was recently used to assess 13 high-volume screening colonoscopists 4 
46
. Among all polypectomies observed and scored blindly, only 64% were judged competent, and 5 
between endoscopists competent resections varied from 30% to 90% of polypectomies. Specific 6 
competencies that varied between endoscopists included achieving the optimal positioning of the 7 
polyp, determining the extent of the lesion, maintaining a stable endoscope position, accurately 8 
placing the snare, achieving an adequate margin of normal tissue, examining the resection site for 9 
residual polyp and removing residual polyp when present. Detection as measured by ADR and 10 
competency in polypectomy had little correlation. Thus, a validated tool is now available both for 11 
teaching polypectomy and assessing polypectomy competency. 12 
 Assessment of patient discomfort and complications of colonoscopy is also essential for 13 
quality assurance purposes. Use of carbon dioxide insufflation reduces post procedural pain and 14 
hospitalization for observation compared to room air insufflation 
47
. Discomfort is also related to the 15 
depth of sedation, but deep sedation is associated with an increased risk for complications, 16 
particularly aspiration pneumonia
48
. The overall risk of complications after colonoscopy increases 17 
when individuals receive anesthesia services 
49
. Sedation practice varies across centers, countries and 18 
continents and seems to be heavily influenced by expectations and beliefs of doctors and patients. 19 
For quality and auditing purposes, doses of sedatives and depth of sedation should also be reported 20 
and related to the comfort score. Recently, the composite performance indicator of colonic 21 
intubation (PICI), combining cecal intubation rate, comfort, and sedation was proposed 
50
. Achieving 22 
PICI was significantly associated with the detection of one or more polyps, compared with 23 
procedures that did not achieve PICI. 24 
 The most ideal quality indicator for colonoscopy, however, is the rate of post-colonoscopy 25 
CRCs. To allow comparison, a clear definition on the taxonomy of interval cancers, including post-26 
colonoscopy cancers, is of utmost importance and has been established 
27
. However, whenever 27 
feasible, post-colonoscopy CRCs should be measured over a long time-span and enabled by accurate 28 
detection of those cancers. This requires large numbers of colonoscopy, structured reporting, and 29 
reliable coupling to a cancer registry. As post-colonoscopy CRCs are relatively rare, this parameter is 30 
less useful as a quality indicator for individual endoscopists, but should rather be used as an indicator 31 
at the level of a center or a national screening program.  32 
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 These and other current quality indicators were gradually developed as new evidence 1 
emerged. Ongoing research will allow development of new indicators that are more accurate and 2 
comprehensive in their depiction of quality. Assessment and benchmarking of those quality 3 
indicators forms the basis for continuous quality improvement. Auditing and benchmarking, including 4 
provision of training to underperformers, demonstrated a benefit on CIR, ADR, post-colonoscopy 5 
CRCs and sedation-use 
51-53
. To facilitate standardized and complete reporting on important quality 6 
indicators, structured terminology and colonoscopy reporting systems should be encouraged 
54-56
.   7 
 8 
ADVANCED DETECTION TOOLS FOR COLORECTAL LESIONS 9 
  From previous studies it is known that adenomas most prone to be missed at colonoscopy 10 
are small (<10 mm), flat and located at the proximal side of haustral folds or the inner curve of the 11 
hepatic or splenic flexure. 
24, 57, 58
 In a systematic review of tandem colonoscopy studies published 12 
between 1991 and 2004, a remarkable 22% pooled miss-rate for all polyps was reported 
57
. The miss-13 
rate for lesions measuring at least 1cm was 2%, for small polyps 13%, and for diminutive polyps 26% 14 
57
. In line with these results, a simulation study using CT-colonography estimated that 7.8% of the 15 
colonic surface is not visualized during standard colonoscopy using current wide-angle colonoscopies 16 
(170 degrees) 
59
.  17 
In the past years, high-definition white light endoscopy has become the standard of care for 18 
endoscopy, and guidelines advice their routine use 
29, 60, 61
.  Besides, several advanced technologies 19 
and devices have been developed aiming to improve polyp detection. These techniques include 20 
advanced imaging techniques as well as techniques that aim to increase visualisation of the colonic 21 
surface (FIGURE A). However, as discussed in the previous paragraph, ascertaining basic quality 22 
measures remains of paramount importance.  23 
When assessing clinical studies on new endoscopic detection techniques, it is important to 24 
realize that blinding for the technique is impossible in these trials. Therefore, close attention should 25 
be given to the quality of such studies, and investigators should try to make the two modalities 26 
comparable in terms of patient population, quality of endoscopists, their experience with the new 27 
techniques as well as all basic quality indicators.   28 
Most advanced imaging techniques are based on the principle that the mucosal structure of 29 
(pre-) malignant lesions differs from the surrounding healthy tissue and consequently differ in their 30 
ability to absorb and reflect light. This trait is then used to depict such lesions differently, thereby 31 
facilitating their detection. These techniques include virtual chromoendoscopy with narrow band 32 
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imaging (NBI), iScan, flexible spectral imaging color enhancement (FICE), blue laser imaging (BLI) and 1 
autofluorescence imaging (AFI). However, despite the plausibility of this approach and the early 2 
positive outcomes for these techniques as a detection-tool 
62-64
, the pooled outcomes of these 3 
studies suggest that ADRs are not conclusively improved by the use of these imaging techniques 
60, 65, 
4 
66
. It seems that when endoscopists become acquainted with this new technique and detect lesions 5 
they did not see before, this also affects their performance with (high-definition) white light 6 
endoscopy 
62, 67
.  7 
From CT-colonography studies it is known that especially adenomas located at the proximal 8 
side of haustral folds or the inner curve of the flexures are more prone to be overlooked at 9 
colonoscopy, as they lie outside the regular field of view of colonoscopy. 
68
 In order to increase 10 
visualisation of the colonic surface aiming to improve adenoma detection rates, several surface 11 
exposing technologies have been proposed. These surface exposing technologies include cap-fitted 12 
colonoscopy, Endocuff or EndoRings assisted colonoscopy, through-the-scope optical devices, full-13 
spectrum endoscopy (FUSE) and (prototype) wide angle view colonoscopies. For these techniques, 14 
results on adenoma detection and miss rates have been variable between studies 
69-77
. This is also 15 
true for the FUSE system: a first study showed large differences in miss rates 
71
, but this positive 16 
result could not be confirmed in a subsequent large comparative randomized trial 
72
. This example 17 
underlines the fact that large, randomized trials in daily practice are required to determine whether 18 
an improved ADR remains true in broader practices and whether the use of these endoscopes and 19 
devices is cost-effective and clinically warranted 
77
. 20 
 21 
CHARACTERIZATION OF LESIONS 22 
For decision-making in the management of colorectal lesions, lesion characterization is 23 
crucial. First of all, the entire surface should be examined for factors associated with deep (>1000 24 
microns) submucosal invasion of cancer.  These factors include morphologic features like ulceration, 25 
changes in the pit pattern, and disruption of the surface vessel pattern
78
. Often changes in the pits 26 
and vascular patterns that denote deep submucosal invasion are evident only in areas of surface 27 
ulceration.  Deep submucosal invasion is associated with a higher risk of lymph node metastasis
79, 80
, 28 
and is generally a contraindication to both EMR and ESD.  Such endoscopic features are generally 29 
specific for deep submucosal invasion (or even greater depth) but lack sensitivity for submucosal 30 
invasion generally
81
.  Thus, the modern endoscopist should be familiar with other endoscopic 31 
features that are associated with an increased risk of submucosal invasion generally, though the 32 
depth of invasion may be superficial (<1000 microns). When superficial submucosal invasion is 33 
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present, endoscopic resection may be considered curative in some cases if it was performed en bloc. 1 
Thus, when these “other” endoscopic factors are present, en bloc resection by EMR or ESD is often 2 
preferred if feasible. These “other” factors associated with submucosal invasion generally include 3 
non-granular morphology (particularly if associated with depression), and the presence of a large 4 
nodule in an otherwise flat lesion (see below)
81, 82
. Recognition of deep submucosal invasion as well 5 
as other features associated with an increased risk of any invasion by non-expert endoscopists  can 6 
be further improved, and training for endoscopic diagnosis for early invasive cancers is urgently 7 
needed to ensure optimal clinical practice for treatment of these lesions 
83
. To systematically 8 
describe a lesion and assess the risk of deep as well as any submucosal invasion, several 9 
morphological classification systems have been developed. These include location, size, Paris 10 
classification, lateral spreading tumor classification (if applicable) and evaluation of the mucosal 11 
surface pattern with high-definition endoscopes and advanced imaging techniques 
84
 (FLOWCHART 12 
1).  13 
The size of a lesion is directly related to the chance that the lesion harbors invasive growth 14 
into the submucosa. One to five mm (“diminutive”) lesions have a very low risk of invasiveness, 15 
whereas 6-9 mm (“small”) lesions have a tiny risk of 0 to 0.4% 
85
. For lesions of 10mm and larger, the 16 
risk of cancer gradually increases from 2.4% for 10 to 20 mm lesions to a maximum of 19.4% for 17 
polyps measuring more than 20 mm in size 
86
. However, measuring polyp size during colonoscopy is 18 
subject to inter-observer variability, and a gold standard is not available. A recent proof-of-concept 19 
simulation study using a visual grid cue during endoscopy to measure polyp-size showed promising 20 
results 
87
 and should be further explored.  As long as objective tools for daily practice are not 21 
available, ideally an open snare or biopsy forceps with known size should be used to size a lesion 22 
before resecting it. 23 
The Paris classification divides polyps into several categories depending on their morphology: 24 
pedunculated (0-1p), sessile (0-1s), slightly elevated (0-IIa), flat (0-IIb), slightly depressed (0-IIc) and 25 
excavated (0-III) 
88
. Especially recognizing and classifying depressed and excavated morphology 26 
seems relevant. While rare, lesions of this specific morphology are associated with an increased risk 27 
of invasive growth. The term laterally spreading type (LST) lesion refers to lesions of at least 10mm 
89
. 28 
For this type of lesions a separate classification is used, dividing these in granular and non-granular 29 
types. An increasing size, non-granular type LSTs and LSTs with a large dominant nodule >10mm in 30 
size are associated with an increased risk of harboring invasive growth 
81, 90-94
.  31 
The introduction of high-definition endoscopes allows for precise evaluation of mucosal 32 
surface patterns, the most helpful tool to predict histopathology of polyps. For colorectal lesions, 33 
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several surface pattern classification systems as the Kudo, NICE, WASP and JNET classification for 1 
both chromoendoscopy and virtual chromoendoscopy have been validated 
78, 95-100
.  2 
Besides assessment of submucosal invasion, accurate characterization could facilitate a 3 
“Resect and Discard” strategy, in which diminutive polyps are resected after endoscopic 4 
characterization but do not have to be submitted for histopathology. Diminutive polyps in the 5 
rectosigmoid endoscopically deemed to be hyperplastic (or at least serrated) at histopathology can 6 
be reasonably left in place 
101
. Only about 2% of lesions deemed hyperplastic in the rectosigmoid are 7 
found to be sessile serrated lesions on histopathology 
102
. In 2011, the American Society of 8 
Gastrointestinal Endoscopy published the so-called Preservation and Incorporation of Valuable 9 
Endoscopic Innovation (PIVI) guideline containing performance thresholds for this purpose 
101
. For 10 
diminutive polyps that are diagnosed with high confidence, in combination with outcomes of 11 
histolopathology assessment of larger polyps and those characterized with low confidence, 12 
endoscopists should achieve at least 90% agreement between surveillance intervals that he/she 13 
predicted by optical diagnosis and the definitive surveillance intervals that are based on 14 
histopathology. Besides, they should achieve at least 90% negative predictive value for neoplastic 15 
polyps in the rectum and sigmoid, i.e. at least 90% of polyps they assess as non-neoplastic are indeed 16 
not neoplastic at histopathology 
101
. However, whereas expert endoscopists are able to achieve the 17 
PIVI-thresholds for diminutive polyps 
103-105
, studies with endoscopists working in daily clinical 18 
practice  have shown conflicting results 
106-111
. This difference could be explained by differences in 19 
time and dedication, but also in training and feedback of performance. Recently, the UK national 20 
health policy has endorsed the Resect and Discard strategy for implementation in clinical practice 
112
.  21 
For optimal cost-effectiveness however, studies evaluating the effect of validated training programs 22 
and regular feedback on PIVI-tresholds in daily practice are essential and underway. Other potential 23 
barriers for implementation of the strategy are acceptability by the public and potential medical-legal 24 
risk of Resect and Discard when the policy has been implemented and there is the inevitable 25 
occurrence of an interval cancer. In these instances the cause of the interval cancer will likely be a 26 
missed lesion nearby in the colon rather than a discarded diminutive lesion. The defense will depend 27 
on development of clear society and institutional policies and stored high-quality photographs of 28 
discarded lesions.  29 
 30 
RESECTION OF LESIONS 31 
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The CARE study demonstrated that the problem of variable performance in colonoscopy also 1 
extends to polypectomy, identifying a threefold difference between endoscopists in rates of effective 2 
polyp resection 
16
. Increasing polyp size and serrated histology also predicted ineffective resection 
16
.   3 
Polyps of all predicted histologic types and sizes identified proximal to the sigmoid colon are 4 
typically resected, though the wisdom of resecting diminutive polyps has recently been challenged 5 
113
. Despite the very low risk of cancer in diminutive lesions, available data on the natural history of 6 
small and diminutive polyps are in general confined to 2-3 years of observation 
85
. These limited data, 7 
in combination with uncertainty about patient acceptance of leaving lesions in place for long 8 
intervals, means that resection of even diminutive lesions other than distal colon hyperplastic polyps 9 
is likely to remain standard for now.  10 
 Table B (TABLE B) shows several current and recent trends in endoscopic resection in the 11 
colorectum. Several resection techniques are currently available (FIGURE B). First, the use of hot 12 
forceps for removal of diminutive polyps has been largely abandoned, both because it is ineffective, 13 
leaving residual polyp in place in 17-53% of lesions 
114
 
115
 and because it creates thermal injury that is 14 
associated with unnecessary risk, especially of perforation. Animal studies show that thermal injury is 15 
much harder to control with hot forceps compared to snaring, even with optimal technique 
116
. 16 
Further, guidelines stipulate that hot forceps should not be used for removal of lesions larger than 5 17 
mm 
117
. Currently, the use of hot forceps in colonoscopy has been essentially reduced to the process 18 
of avulsion during EMR, in which flat areas (often associated with submucosal fibrosis) that are 19 
resistant to snaring, are removed with forceps (either hot or cold) rather than ablated 
118
. 20 
Second, the use of cold resection techniques rather than hot resection is increasing generally 21 
in polyp resection, primarily because it reduces risks. Cold resection has been found histologically to 22 
cause less injury to submucosal vessels compared to hot snaring 
119
.  In a randomized controlled trial 23 
comparing cold to hot snaring of small polyps in anticoagulated patients, cold snaring reduced the 24 
risk of delayed hemorrhage from 14% to 0% 
119
.  Similarly, conversion to cold snaring reduced the risk 25 
of delayed hemorrhage in an observational study performed in a single practice 
120
. Several 26 
randomized controlled trials found that rates of complete polyp resection with cold snaring were not 27 
different from hot snaring 
121-123
. One study found that resection of small polyps with a thin-wire stiff 28 
snare made specifically for cold snaring resulted in superior complete resection rates compared to a 29 
standard snare 
119
, but results have been inconsistent 
124
. Cold snaring is also considerably more 30 
time-efficient that hot snaring in some studies, reducing total procedure time by more than 5 31 
minutes 
125, 126
. This is likely because there is no need to set up the cautery and patient grounding 32 
equipment before proceeding with resection. Cold snaring of larger lesions, or when mechanical 33 
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tension is needed for transection, commonly leaves a cord of white submucosal tissue protruding 1 
from the defect, but the cord is devoid of residual polyp and represents submucosal tissue 
127
. The 2 
cold resection technique has been extended to lesions over 1 cm in size 
128
 and also to performance 3 
of endoscopic mucosal resection (EMR), particularly for serrated lesions, and it appears effective in 4 
initial studies 
129
 and is nearly devoid of complications. Additional data regarding effectiveness of 5 
cold EMR are needed.   6 
A third trend is toward cold snare resection of diminutive and small lesions over cold forceps 7 
resection. When polyps reach a size of 4mm, snare resection is more effective and efficient 8 
compared to cold forceps methods 
130
. Forceps methods are particularly inappropriate if piecemeal 9 
resection is required. A general rule that seems reasonable is that forceps resection of 1-3mm polyps 10 
is appropriate, particularly if it can be accomplished in one bite, and large capacity and jumbo 11 
forceps are more effective in this regard compared to standard forceps 
131
. 12 
A fourth trend is an increasing use of EMR over standard snare polypectomy techniques.  13 
EMR has emerged as the treatment as choice for nearly all flat and sessile lesions ≥ 20mm in size in 14 
the colorectum. A series of studies performed by multiple groups of expert endoscopists has 15 
delineated the effectiveness, safety, and superiority of EMR over surgical resection for lesions in this 16 
size group 
132-134
.  Modern EMR depends closely on advanced imaging and interpretation skills. In the 17 
absence of overt endoscopic evidence of deep submucosal invasion, morphologic features such as a 18 
nongranular surface, a large sessile component, and depression are predictors of submucosal of 19 
invasion 
81, 94
 that warrant en bloc resection when feasible, and appropriate handling of resected 20 
specimens by the endoscopist and pathologist. EMR is particularly important for serrated lesions, 21 
because submucosal injection of a contrast agent clearly delineates the lesion perimeter during 22 
piecemeal removal 
135, 136
. The technique is considered appropriate for serrated lesions in the 10-23 
20mm size range 
137
. Inclusion of a contrast agent stains the submucosa so that any muscle injury is 24 
readily seen (as the target sign) leading to easy repair and prevention of delayed perforation 
138
. 25 
Submucosal injection fluids that are more viscous than saline create superior submucosal cushions 26 
and improve the efficiency of resection 
139
.  Modern EMR emphasizes resection by snaring, with 27 
avulsion as a rescue method, rather than ablation of residual visible polyp tissue 
118
. Cold resection or 28 
use of microprocessor controlled electrocautery with emphasis on cutting over coagulation current 29 
are increasingly utilized 
132
. Some experts endorse performance of EMR under water and without 30 
submucosal injection. When the lumen is filled with water, the mucosa “floats” away from the 31 
muscularis propria, providing a margin of safety for resection in the submucosal plane without 32 
submucosal injection. Under water EMR allows en bloc resection of a larger group of lesions 
140
, 33 
because submucosal injection typically increases lesion size. Potential disadvantages include difficulty 34 
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identifying muscle injury because of absence of submucosal staining, and peritoneal contamination if 1 
perforation occurs. 2 
Endoscopic submucosal dissection (ESD) has advantages compared to EMR including a lower 3 
recurrence rate at first follow up. Also, a group of patients with superficial (SM1; upper one-third) 4 
submucosal invasion can avoid surgery compared to similar patients after piecemeal EMR 
141
.  5 
Despite these advantages, the expansion of ESD in western countries is often delayed by low 6 
numbers of experienced practitioners, long learning curves for ESD, long procedure times, higher 7 
perforation rates compared to EMR, and lack of appropriate reimbursement. Advances in ESD 8 
technology, combined with the attractiveness of en bloc resection, are likely to increase the 9 
utilization of colorectal ESD in western countries over time. However, effective use of ESD depends 10 
on the appropriateness of the clinical indication 
142
. An emerging area of resection that is receiving 11 
increasing attention and bypasses both EMR and ESD is the full thickness resection device 
143
. This 12 
endoscopic technique has been developed to allow accurate diagnosis and potentially definitive 13 
treatment for lesions invading any depth of the submucosal layer of the colonic wall. It combines 14 
resection of the entire colonic wall performed after secure closure of the expected defect by the use 15 
of a modified over-the-scope-clip mounted on a cap with a preloaded snare.  16 
 17 
FUTURE TRENDS 18 
Table C (TABLE C) lists reasonable expectations for developments in colonoscopy relative to 19 
cancer prevention and cost-effectiveness of colonoscopy for neoplasia management. Several of the 20 
predicted developments constitute major paradigm shifts in colonoscopy application. However, given 21 
the steady advances in instrumentation, examination effectiveness, and polypectomy technique, 22 
reconsideration of fundamental approaches is appropriate and necessary. 23 
There will be continued challenges to the role of colonoscopy as a primary screening 24 
strategy. New screening strategies based on risk stratification 
144
 may direct screening colonoscopy to 25 
the highest prevalence screening populations, while lower prevalence populations are screened with 26 
inexpensive, noninvasive, and highly specific tests like FIT. However, the challenges to achieving 27 
adherence to repetitive fecal screening outside of organized screening programs will make screening 28 
colonoscopy, with its potential for long term protection, continue to be an attractive screening 29 
approach in the opportunistic screening setting 
145
. Continued progress in combined assays such as 30 
FIT-fecal DNA and other molecular markers can be expected to further displace screening 31 
colonoscopy, though for programmatic screening lower cost DNA tests are needed 
146, 147
. As a 32 
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further development, these tests would ideally only detect those premalignant lesions that are close 1 
to developing into cancer. If this becomes reality, screening colonoscopies are likely to be replaced 2 
by therapeutic colonoscopies in those patients with relevant lesions at a truly high risk for CRC.  3 
Second, there are potential consequences of the quality movement and the trend toward 4 
higher ADRs and the detection of increasing numbers of diminutive lesions. One consequence is that 5 
patients in the 60-70 year range with negative colonoscopies performed by high ADR colonoscopists 6 
would be reasonably expected to have a very low risk of ever developing CRC. Such patients might be 7 
advised to either stop screening or have only once or twice in a lifetime a screening colonoscopy. 8 
Second, for high ADR colonoscopists, the low-risk cohort of adenoma bearing patients will be 9 
expanded. For example, many 5-10 year examination intervals could be expected for 1-4 small 10 
tubular adenomas when the colonoscopies are performed by a high ADR examiner 
148
.  However, we 11 
expect that quality assurance, and consistent use of techniques and potentially also devices proven 12 
to enhance detection, will reduce the variation between high and low ADR examiners by time.   13 
Also, the application of artificial intelligence (AI) technology will likely change polyp detection 14 
and differentiation practice. Detection programs will provide real-time assessment of the adequacy 15 
of colonoscope tip deflection and cleaning to expose all mucosa 
149
, while simultaneously highlighting 16 
potential lesions. Strategies such as Resect and Discard, that eliminate the pathologic assessment of 17 
diminutive polyps or at least diminutive adenomas, are likely to emerge as accepted clinical 18 
strategies 
15
. Previously hampered by poor performance among community endoscopists, the 19 
application of artificial intelligence (AI) technology to the prediction of colon polyp histologies will 20 
make strategies like Resect and Discard universally feasible. These achievements are likely to further 21 
reduce operator dependence in colonoscopy.  22 
In the not-too-distant future, the combination of these trends may completely change the 23 
face of colonoscopy. Average-risk individuals participating in organized screening programs might be 24 
systematically invited to perform a highly selective stool-test at home. Those individuals with 25 
colorectal lesions at high-risk for CRC development will be invited to undergo a therapeutic 26 
colonoscopy, in which artificial intelligence will help with the detection of these lesions. After 27 
detection, polyp histology will be predicted, potentially followed by advice on the optimal resection 28 
technique and whether histopathological analysis is recommended. The endoscopist will perform en-29 
bloc resection of the lesion using easier, less laborious, and safer techniques than those currently 30 
available. Finally, patient-selection for surveillance colonoscopies may also be based on the 31 
outcomes of stool-tests instead of risk-stratification at the time of the last colonoscopy.  32 
 33 
34 
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FIGURE LEGENDS: 27 
Figure 1:   Top: Proposed systematic approach for structured lesion description including 28 
morphological features associated with deep submucosal invasion. 29 
Bottom: Schematic overview of several endoscopic resection methods. 30 
 31 
Figure 2: Advanced imaging techniques. a; picture of a pT1sm2 adenocarcinoma using narrow band 32 
imaging, b; picture of a tubular adenoma with low-grade dysplasia using autofluorescence imaging, c; 33 
picture of a sessile serrated lesion without dysplasia using linked color imaging, d; picture of a tubular 34 
adenoma with low-grade dysplasia using blue light imaging. 35 
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Table A. Minimum recommended registration of preprocedure, intraprocedure and postprocedure 
quality indicators based on current prevailing international guidelines 
29-32
.  
Quality requirement Description Recommended 
minimum if 
applicable 
Preprocedure   
 Accreditation and 
professional registration 
Accreditation conforming to the levels proposed by 
scientific society of gastroenterology and 
registration with a professional gastroenterology 
society  
- 
 Number of 
colonoscopies 
Number of (screening) colonoscopies performed 
per year 
≥ 500 (lifetime) 
 Number of 
polypectomies 
Number of polypectomies performed per year ≥ 50 
(lifetime) 
Intraprocedure   
Completeness of exam   
 (Unadjusted) cecal 
intubation rate 
The percentage of colonoscopies with a complete 
cecum intubation 
≥ 90% 
 Bowel preparation The percentage of colonoscopies where the colon 
is sufficiently clean to be able to inspect the 
mucosa well (BBPS ≥ 6) 
≥ 90% 
 Withdrawal time The percentage of negative colonoscopies with an 
withdrawal time  
≥ 6 minutes 
Detection rates   
 Cancer detection rate The percentage of colonoscopies where (more 
than) one cancer has been detected 
- 
 Adenoma detection rate 
(ADR) 
The percentage of colonoscopies where (more 
than) one adenoma has been detected 
≥ 20% 
 MAP The mean number of adenomas per procedure 
(colonoscopy) 
- 
 PSPDR  The percentage of colonoscopies where (more 
than) one proximal serrated polyp has been 
detected  
≥ 5% 
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Removal rates   
 Polyp removal rate The percentage of polyps removed of the total 
number of detected polyps during the colonoscopy 
≥ 90% 
 Polyp retrieval rate The percentage of retrieved polyps for histological 
evaluation of the total number of polyps detected 
during the colonoscopy 
≥ 90% 
Tattoo placement   
 Tattooing The percentage of suspected cancers given a 
tattoo, except from cancers located in the cecum 
and up to 4 cm from the dentate line 
100% 
Postprocedure   
Patient satisfaction   
 Comfort Score The percentage of colonoscopies in which the 
participant experiences moderate or severe 
discomfort (according to the GCS) 
≤ 10% 
Wellbeing of patients   
 Complication record Keeping a complication record - 
 Complications during 
colonoscopy 
The percentage of colonoscopies performed by the 
endoscopists where a complication occurs (up to 
30 days after the procedure) 
- 
  Perforation rate 
colonoscopy 
The perforation rate for colonoscopies performed 
by the endoscopist (up to 30 days after the 
procedure) 
- 
  Perforation rate 
polypectomy 
The perforation rate for colonoscopies with 
polypectomy performed by the endoscopist (up to 
30 days after the procedure) 
- 
  Polypectomy 
bleeding 
The percentage of colonoscopies with 
polypectomy performed by the endoscopist , 
where complicated bleeding occurs (up to 30 days 
after the procedure) 
- 
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Table B. Current and recent trends in polyp resection during colonoscopy. 
1. Hot forceps are used only for avulsion of flat residual polyp that can’t be snared 
during EMR; hot forceps have no advantage and result in unnecessary risk in the 
resection of diminutive polyps 
2. Cold resection techniques continue to expand to an ever enlarging group of target 
lesions; including cold EMR 
3. Cold snare resection is preferred over cold forceps resection even for diminutive 
lesions; snaring is more effective and efficient than forceps resection 
4. The target set of lesions for EMR over standard polypectomy techniques continues to 
expand; for serrated lesions the threshold for performance of EMR should be 10-15 
mm; all sessile and flat lesions ≥ 20 mm should generally be treated by EMR rather 
than use of standard techniques 
5. Several trends in the technical performance of EMR have emerged 
a. Classification schemes based on morphology (e.g. Paris classification and 
non-granular vs granular) and blood vessel and pit classifications using image 
enhanced endoscopy allow prediction of cancer risk, appropriateness of 
endoscopic resection, and the need for en bloc resection 
b. High definition instruments allow delineation of residual polyp during 
resection and at follow-up 
c. Several viscous injection solutions perform better than saline 
d. Contrast in the injection fluid defines lesion boundaries and stains the 
submucosa, permitting recognition of muscle injury 
e. Microprocessor controlled currents emphasizing cutting over coagulation 
current reduce thermal injury and may reduce complications 
f. Visible polyp that can’t be snare resected should be avulsed with forceps 
rather than ablated 
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Table C.  Predicted future trends in the use of colonoscopy for colorectal cancer detection and 
prevention 
1. Screening colonoscopy in organized screening programs will be progressively 
reduced in low-risk persons by therapeutic colonoscopies, as inexpensive and  highly-
selective non-invasive fecal tests will identify patients with colorectal lesions at high-
risk for CRC development 
2. Patients with one or two negative colonoscopies after age 50 by high level detectors 
(high ADR endoscopists) will be recommended to forego further colorectal cancer 
screening based on minimal residual lifetime risk 
3. The low risk adenoma bearing cohort recommended to undergo next examination in 
5-10 years will, when examination is performed by high ADR colonoscopists, be 
expanded to include persons with 3-4 small or diminutive tubular adenomas with 
low-grade dysplasia 
4. Operator dependence in colonoscopy performance will be progressively reduced by 
quality improvement programs and technical improvements 
5. Artificial intelligence (deep learning) programs will provide real-time assessment of 
withdrawal technique, assistance in lesion identification, and prediction of histology 
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